Chapter 80: Chapter 77 At that time, two verses of poetry were recited..... (Part 1)
"Xiaoxu, are you planning to start a company?"
In the office.
Upon hearing Tian Liangwei’s words, Xu Yun instinctively paused.
But soon, he calmly nodded:
"Yes."
Xu Yun’s response was within Tian Liangwei’s expectations, given the commercial value of the Fifth Generation Imidacloprid is evident, even to players outside the industry.
Tian Liangwei thought for a moment, motioned for Xu Yun to sit, and said:
"So, Xiaoxu, do you have any ideas about the company’s preparation?"
Upon hearing this, Xu Yun didn’t speak, but picked up his teacup and took a sip, simply looking at his teacher.
A few seconds passed.
They both began to laugh simultaneously.
Xu Yun, while laughing, poured a cup of tea for Tian Liangwei, saying:
"Teacher, don’t forget, Ke Da still holds 30% patent rights for the Fifth Generation Imidacloprid.
The school won’t give up on me, and I can’t leave our school.
So, you don’t have to test me anymore. Just tell me what the school plans to do, right?"
Having been with Ke Da for nearly 20 years across two lifetimes, Xu Yun’s feelings for Ke Da naturally need no further explanation.
Humans are not plants, who can be emotionless?
Even after he left for the sea, he chose to remain connected with Ke Da, and he would visit teachers and classmates during holidays.
From a rational perspective, Ke Da is undoubtedly an excellent partner.
Xu Yun’s current situation is having technology but lacking funds.
Of course.
The funds here refer to substantial amounts.
For example, he has saved over sixty thousand yuan in his Alipay over the years, but under current circumstances, sixty thousand yuan won’t make much of a ripple.
Therefore, his only option is to seek cooperation with institutions.
Whether official or private, or even overseas institutions, or perhaps some vampire-like venture or private equity funds.
Among all these potential candidates, Ke Da almost outshines others in every aspect.
Firstly, Ke Da is backed by the Science Institute, with many top-notch academicians within the school,
in terms of both status and background, it can be said to be a local giant.
Secondly, Ke Da has rich experience in enterprise investment and management, with several direct investment institutions, and a broad commercial landscape.
Of course.
Not only Ke Da is engaging in industry, almost all domestic and foreign universities are currently walking this path.
For instance, the renowned Harvard even established an alumni investment fund directly for purchasing private debt bonds.
Stanford University has established multiple venture capital institutions, investing in more than three hundred projects annually.
In recent years, they have already covered Stealing Country, and it is estimated that in some time, they will reach local areas.
It can be said that today’s universities are no longer the places focused solely on academics, as many perceive them to be.
After all, many can’t afford to just be academic-focused; the future positioning of universities is a mature industry-research-education module, which is an inevitable trend.
For example, Shuimu is currently a shareholder in 14 listed companies, with stocks named 000938 and 002049 each valued at over 60 billion.
Ke Da represents 688027, with a market value of more than 20 billion.
This mature corporate management system is undoubtedly a huge support for the current Xu Yun—you can have him do research or write papers, but when it comes to corporate management, Xu Yun is entirely inexperienced.
A recent example is the probing from Senxia Pharmaceutical a few hours ago.
Is Senxia Pharmaceutical’s approach disgusting?
The answer is certainly yes.
But from a business standpoint, it is indeed an operation Xu Yun himself admires.
Behind such operation, there must be a seasoned expert guiding it.
Such experts, if you ask Xu Yun to find one, might run into one or two by chance in alumni circles, but to organize a complete company operating system, this is almost an unachievable task.
If so, why not leave such worries to others?
On the other hand, Ke Da is also evidently unwilling for Xu Yun to seek cooperation with outsiders—it’s like pre-infringement, clearly your own things, why share the proceeds?
Both parties have related demands and emotional foundations.
Thus, cooperating naturally becomes a win-win move.
Tian Liangwei then made a call, communicating with someone unknown for a few minutes.
Half an hour later.
A thirty-something, suit-wearing, middle-aged man with a little mustache arrived in the office.
Wang Qingchen then took Chang Licheng and left politely.
"Xiaoxu, let me introduce you."
Tian Liangwei welcomed the middle-aged man into the office and introduced:
"This is Mr. Zheng Zu, the secretary-general responsible for investments at Ke Da Innovation Fund."
Xu Yun politely shook hands with Zheng Zu:
"Hello, Secretary Zheng."
Having spent many years at Ke Da, Xu Yun naturally had heard of Zheng Zu.
Generally speaking.
The head of a fund is often the chairman, while the secretary-general is the designated core assistant.
However, college funds are different. University venture fund chairmen typically serve as trustees acting like a business card, with the secretary-general being the actual person in charge.
A saying goes: "Everyone lifts the flower palanquin," Xu Yun’s politeness was naturally met with enthusiasm from Zheng Zu:
"Hello, hello, I’ve long heard of God Xu’s great name, seeing you today, indeed young and talented, like climbing Mount Tai and floating to the eighth lunar month."
Starting with two lines of poetry, this secretary-general seems like an old literature enthusiast.
After the commercial flattery ended, Tian Liangwei first informed internal lines to set his office status to unavailable, then led Xu Yun and Zheng Zu to the tea table, initiating the conversation:
"Xiaoxu, Old Zheng, since both parties are interested, let’s be straightforward and set the framework first, what do you both think?"
Upon hearing this, Xu Yun instinctively exchanged a glance with Zheng Zu and said in unison:
"I have no problem."
"Good."
Tian Liangwei nodded and said to Zheng Zu:
"Mr. Zheng, next, why don’t you introduce a bit?"
Zheng Zu subtly leaned his body, placing his left elbow on the sofa armrest, while his right hand rested on his left wrist as if checking a pulse:
"Dr. Xu, Academician Tian, as you both know, establishing a company, the most important thing is the issue of equity distribution.
Generally, the shares during the establishment of a company are divided according to the investment amount.
For example, if registered capital is set to one million, A contributes three hundred thousand to occupy 30%, B contributes one hundred thousand to occupy 10%.
However, Xiaoxu, your situation is rather special, so the fund’s opinion on this side is to let you contribute shares through technology."
Xu Yun quietly listened to Zheng Zu’s introduction, slightly nodded, indicating he had no issue.
Contributing shares through technology, also known as technical partnership.
In real-life scenarios, the biggest problem for this type of partner is often being valued initially but kicked out later.
However, Xu Yun isn’t worried about this situation—those technical partners who got kicked supposedly "contributed shares through technology," were mostly not genuine intellectual property.
Real intellectual property is protected as formal rights by the 27th clause of the Company Law, particularly for university incubation funds like Ke Da Innovation Fund, where the legal framework is more restrictive.
Moreover, although Ke Da’s subsidiaries have had some disputes before, these mainly originated from disagreement within the framework.
For example, personnel appointments, research funding allocation, etc., never has there been a situation of kicking out due to contributing shares through technology against rules.
Later Xu Yun thought for a moment and said:
"Secretary Zheng, contributing shares through technology is fine, but I also have a request."
Zheng Zu and Tian Liangwei exchanged a glance:
"Go ahead."
"The product we intend to launch from the company is certainly going to be Fifth Generation Imidacloprid, right?"
"Of course."
"So, if I continue to break through with other technological barriers in the future, how should this portion of earnings be distributed?"
....